 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- | umbilical cord mesenchymal stem cells / Vinmec
Enrollment closed, Enrollment change, Trial completion date, Stroma: Mesenchymal Stem/Stromal Cell Therapy in the Treatment of Frailty (clinicaltrials.gov) - Jun 6, 2024
P1/2, N=158, Active, not recruiting, Sponsor: Vinmec Research Institute of Stem Cell and Gene Technology
Recruiting --> Active, not recruiting | N=44 --> 158 | Trial completion date: Nov 2023 --> Dec 2024
- | umbilical cord mesenchymal stem cells / Vinmec
Trial completion: Umbilical Cord Mesenchymal Stem Cells Transplantation in the Treatment of Bronchopulmonary Dysplasia (clinicaltrials.gov) - Jun 3, 2024
P1, N=10, Completed, Sponsor: Vinmec Research Institute of Stem Cell and Gene Technology
Recruiting --> Active, not recruiting | N=44 --> 158 | Trial completion date: Nov 2023 --> Dec 2024 Unknown status --> Completed
- | umbilical cord mesenchymal stem cells / Vinmec
Trial completion, Stroma: Umbilical Cord Mesenchymal Stem Cells Transplantation in the Treatment of Chronic Obstructive Pulmonary Disease (clinicaltrials.gov) - Jun 3, 2024
P1/2, N=40, Completed, Sponsor: Vinmec Research Institute of Stem Cell and Gene Technology
Unknown status --> Completed Recruiting --> Completed
- | umbilical cord mesenchymal stem cells / Vinmec
Enrollment open, Trial completion date, Trial primary completion date, Stroma: Mesenchymal Stem/Stromal Cell Therapy in the Treatment of Frailty (clinicaltrials.gov) - Apr 18, 2023
P1/2, N=44, Recruiting, Sponsor: Vinmec Research Institute of Stem Cell and Gene Technology
Recruiting --> Completed Not yet recruiting --> Recruiting | Trial completion date: Nov 2022 --> Nov 2023 | Trial primary completion date: Nov 2021 --> Sep 2022
- | umbilical cord mesenchymal stem cells / Vinmec
Journal: Cytokine-primed umbilical cord mesenchymal stem cells enhanced therapeutic effects of extracellular vesicles on osteoarthritic chondrocytes. (Pubmed Central) - Nov 18, 2022
Moreover, TGFβ-primed UCMSCs secreted EVs that could upregulate the expression of chondrogenesis markers (COL2 and ACAN) and downregulate fibrotic markers (COL1 and RUNX2) in chondrocytes. Hence, priming UCMSCs with cytokines can deliver selective therapeutic effects of EV treatment in OA and chondrocyte-related disorders.
- | umbilical cord mesenchymal stem cells / Vinmec
Journal: Effects of Extracellular Vesicles Secreted by TGFβ-Stimulated Umbilical Cord Mesenchymal Stem Cells on Skin Fibroblasts by Promoting Fibroblast Migration and ECM Protein Production. (Pubmed Central) - Aug 27, 2022
On the contrary, the protein levels of total collagen and elastin released by fibroblasts were greater in the cell groups treated with EVs compared to EV-depleted conditions; particularly elastin associated with TGFβ-stimulated UCMSCs. These data indicate the potential roles of EVs from UCMSCs in protecting skin from aging by promoting ECM protein production.
- | umbilical cord mesenchymal stem cells / Vinmec
Journal: Human Umbilical Cord Mesenchymal Stem Cells for Severe Neurological Sequelae due to Anti-N-Methyl-d-Aspartate Receptor Encephalitis: First Case Report. (Pubmed Central) - Jul 12, 2022
Cerebral atrophy was reduced on brain magnetic resonance imaging (MRI). Overall, the outcomes of this patient suggest a potential cell therapy for autoimmune encephalitis and its neurological consequences.
- | umbilical cord mesenchymal stem cells / Vinmec
New P1/2 trial, Stroma: Mesenchymal Stem/Stromal Cell Therapy in the Treatment of Frailty (clinicaltrials.gov) - Jun 9, 2021
P1/2, N=44, Not yet recruiting, Sponsor: Vinmec Research Institute of Stem Cell and Gene Technology
- | umbilical cord mesenchymal stem cells / Vinmec
Trial primary completion date, Stroma: Umbilical Cord Mesenchymal Stem Cells Transplantation in the Treatment of Chronic Obstructive Pulmonary Disease (clinicaltrials.gov) - Apr 22, 2021
P1/2, N=40, Recruiting, Sponsor: Vinmec Research Institute of Stem Cell and Gene Technology
Overall, the outcomes of this patient suggest a potential cell therapy for autoimmune encephalitis and its neurological consequences. Trial primary completion date: Nov 2020 --> Jul 2021
- | umbilical cord mesenchymal stem cells / Vinmec
New P1/2 trial, Stroma: Umbilical Cord Mesenchymal Stem Cells Transplantation in the Treatment of Chronic Obstructive Pulmonary Disease (clinicaltrials.gov) - Jun 15, 2020
P1/2, N=40, Recruiting, Sponsor: Vinmec Research Institute of Stem Cell and Gene Technology
- | umbilical cord mesenchymal stem cells / Vinmec
New P1 trial: Umbilical Cord Mesenchymal Stem Cells Transplantation in the Treatment of Bronchopulmonary Dysplasia (clinicaltrials.gov) - Aug 19, 2019
P1, N=10, Recruiting, Sponsor: Vinmec Research Institute of Stem Cell and Gene Technology